Drug intelligence / Profile preview

DMXB-A-SR

Development stage: Phase 2
Lead developer: Taiho Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DMXB-A-SR is a sustained-release formulation of DMXB-A (also known as GTS-21 or DMXBA), a partial agonist at neural nicotinic acetylcholine receptors (nAChRs) with selectivity for the α7 subtype. It has been investigated for its potential to improve cognitive function and memory in patients with schizophrenia. The sustained-release formulation was developed to provide more consistent clinical improvement compared to the standard formulation by maintaining more stable blood levels over time.

Other names: 3-2,4 dimethoxybenzylidene anabaseine sustained release

Targets

CHRNA7 (α7 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on DMXB-A-SR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMXB-A-SR.

Explore the full profile